Heart failure patients with lung infections recovered faster and had fewer hospital readmissions when treated with sacubitril/valsartan compared to conventional therapy.
Lower 2-year readmission ratePatients receiving sacubitril/valsartan had fewer hospital readmissions over 2 years compared to conventional heart failure treatment
What the researchers found
Patients receiving sacubitril/valsartan experienced faster resolution of chest tightness, shortness of breath, cough, and lung crackles compared to the control group. BNP (brain natriuretic peptide, a marker of heart stress) decreased more in the treatment group. Inflammatory markers IL-6, TNF-α, and procalcitonin also improved more with sacubitril/valsartan.
Heart function improved significantly in the treatment group but not the control group. Clinical lung infection scores and organ failure scores were better with treatment. Over 2 years, the readmission rate was lower in the sacubitril/valsartan group, though mortality did not differ.
Why it matters
Heart failure patients who develop lung infections face a dangerous combination. The infection worsens heart function, and heart failure impairs the immune response. Sacubitril/valsartan works by blocking neprilysin (which normally breaks down natriuretic peptides), increasing their levels and reducing heart stress. This study suggests the drug may have additional anti-inflammatory benefits in the setting of infection.
The numbers in context
- 89 patients (48 treatment, 41 control)
- BNP, IL-6, TNF-α, and PCT all decreased more with sacubitril/valsartan
- Faster symptom resolution in treatment group
- Lower hospital readmission rate at 2 years (p < 0.05)
- No mortality difference between groups (p > 0.05)
- No significant difference in adverse reactions (p > 0.05)
How the study worked
Retrospective study of 89 patients with heart failure and lung infections treated at Dongying People's Hospital in China from January 2019 to May 2020. The control group (41 patients) received conventional treatment. The study group (48 patients) received sacubitril/valsartan in addition to conventional treatment. Outcomes included symptom resolution time, biomarkers (BNP, IL-6, TNF-α, PCT), cardiac function, clinical scores, and 2-year follow-up for readmission and death.
Who was studied
89 heart failure patients with concurrent pulmonary infections at a single Chinese hospital
What this study cannot tell us
This was a small retrospective study at a single hospital with no randomization. The treatment group was slightly larger, suggesting possible selection bias. Without randomization, differences between groups may reflect baseline patient characteristics. The small sample limits the power to detect mortality differences. The 2-year follow-up is based on readmission records, which may not capture all events.
How to read the evidence
Rated preliminary: small retrospective study at a single hospital with no randomization and unequal group sizes.
When this study was published
Published in 2024 using data from 2019–2020. Pre-COVID era data, which is relevant since COVID has changed pneumonia management.
The bigger picture
Heart failure and lung infections create a dangerous cycle — each worsens the other. Sacubitril/valsartan works by blocking natriuretic peptide degradation, which may help both heart function and inflammation resolution.
Questions still open
- Would a larger randomized trial confirm these results?
- Is the benefit from improved heart function, anti-inflammatory effects, or both?
Common questions
What does sacubitril/valsartan do?
Why is a lung infection dangerous for heart failure patients?
Read the original research
Efficacy of Sacubitril Valsartan sodium tablets in patients with heart failure combined with pulmonary infection and long-term recurrence rate.
American journal of translational research, 16(8), 3742-3750
Citation
Qin, Xiao; Li, Nannan; Zhang, Cuifen; Li, Shanshan; Bu, Fanli. (2024). Efficacy of Sacubitril Valsartan sodium tablets in patients with heart failure combined with pulmonary infection and long-term recurrence rate.. American journal of translational research, 16(8), 3742-3750. https://doi.org/10.62347/ESYO5136